<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495766</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-MS-02</org_study_id>
    <nct_id>NCT02495766</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stromal Cells for Multiple Sclerosis</brief_title>
  <acronym>EMMES</acronym>
  <official_title>Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vall d'Hebron Research Institute (VHIR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of cryopreserved autologous adult bone-marrow mesenchymal
      stromal cells (BM-MSC) in patients with active multiple sclerosis, compared to placebo.

      Patients will be allocated to one of the 2 treatment arms (BM-MSC or placebo)and at month 6,
      the treatment will be crossed to receive the other product. The objective is to assess the
      safety of a single infusion BM-MSC, and to explore its efficacy in these patients.

      Patients will be evaluated at month 12 and will be followed-up for a total of 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, there is no effective therapy to cure multiple sclerosis (MS). Immunomodulatory
      therapies are useful in reducing the frequency of inflammatory processes (relapses) but don't
      delay significantly the progression of the disease, prevent long term disability or induce
      the repair of damaged tissue. This proposal contemplates the use of adult autologous bone
      marrow mesenchymal stromal cells (BM-MSC) as an alternative therapeutic strategy to treat
      patients with active MS. This is a randomized, double blind, crossover clinical trial in
      which 8 patients with active forms of MS and moderate disability will enter the trial with
      the primary objective of assessing the safety and tolerability of a single intravenous
      infusion of BM-MSC. Secondary objectives are to assess the efficacy by gadolinium enhancing
      lesions though magnetic resonance imaging, neurophysiological effects and immunological
      effects. Once randomized, patients will undergo BM extraction and once confirmed the
      availability of the needed dose, they will be randomized to one of the 2 treatment arms
      (BM-MSC named XCEL-MC-ALPHA, or placebo). XCEL-MC-ALPHA will be cryopreserved for all
      patients regardless the allocated arm. At month 6, the treatment will be crossed. Patients
      will be evaluated at month 12 and will be followed-up for a total of 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of MRI Gd-enhancing lesions</measure>
    <time_frame>12 months</time_frame>
    <description>Imaging procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Outbreaks</measure>
    <time_frame>12 months</time_frame>
    <description>Medical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDDS) score</measure>
    <time_frame>12 months</time_frame>
    <description>Quantification of disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of lesions visualized on T2 sequence</measure>
    <time_frame>12 months</time_frame>
    <description>Imaging procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment A: XCEL-MC-ALPHA/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Placebo/XCEL-MC-ALPHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-MC-ALPHA</intervention_name>
    <description>Single infusion</description>
    <arm_group_label>Treatment A: XCEL-MC-ALPHA/Placebo</arm_group_label>
    <arm_group_label>Treatment B: Placebo/XCEL-MC-ALPHA</arm_group_label>
    <other_name>Bone-marrow mesenchymal stromal cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single infusion</description>
    <arm_group_label>Treatment A: XCEL-MC-ALPHA/Placebo</arm_group_label>
    <arm_group_label>Treatment B: Placebo/XCEL-MC-ALPHA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 60 years of age

          -  Patients with MS

          -  Relapsing-remitting or secondary progressive MS

          -  Patients to whom are not indicated or are not in a position to initiate treatment with
             disease-modifying drugs

          -  Expanded Disability Status Scale (EDDS) score &lt;6.5

          -  Nine T2 lesions at least

          -  Active multiple sclerosis as defined either by 1 outbreak in the last year or at least
             one Gadolinium-enhancing lesion in the last 6 months

          -  Signed informed consent form

        Exclusion Criteria:

          -  Interferon beta or glatiramer acetate 3 months prior the screening

          -  Natalizumab or fingolimod in the 6 months prior the screening

          -  Mitoxantrone, cyclophosphamide or other immunosuppressive therapy at any time

          -  Has received an experimental treatment within 3 months prior the screening

          -  MS outbreak within the 4 weeks prior the randomization

          -  Serum creatinine&gt; 2.0 mg/dl

          -  Infectious disease active or uncontrolled

          -  Fertile patients who are not using a suitable method of contraception

          -  Pregnant or lactating woman

          -  Immunodeficiency

          -  Positive serology to HIV, Hepatitis B, Hepatitis C or syphilis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Montalban, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Vall Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net</url>
    <description>Blood and Tissue Bank of Catalonia</description>
  </link>
  <link>
    <url>http://xcelia.eu</url>
    <description>Advanced Therapies Division of the Blood and Tissue Bank</description>
  </link>
  <link>
    <url>http://www.cem-cat.org/</url>
    <description>Multiple Sclerosis center of Catalonia</description>
  </link>
  <link>
    <url>http://www.vhir.org</url>
    <description>Vall d'Hebron Research Institute</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Bone marrow mesenchymal stromal cells</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Demyelinating Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

